The outcomes from the randomized, open-label, phase III CATNON trial in patients with 1p/19q non–co-deleted anaplastic gliomas indicated futility of concurrent temozolomide with radiation and adjuvant temozolomide in patients with IDH 1/2 wildtype tumors. Here, IDH2 is linked to grade III glioma.